camptothecin has been researched along with Carcinogenesis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bešlija, S; Gatalica, Z; Vranić, S | 1 |
| Deneka, AY; Gaponova, AV; Golemis, EA; Haber, L; Kopp, MC; Nikonova, AS | 1 |
| Bohrer, LR; He, Y; Huang, H; Pan, Y; Wang, L; Zhao, Y | 1 |
| Carriquiriborde, M; Gentil, F; Gentili, C; Gigola, G; Martín, MJ; Zwenger, A | 1 |
| Aguilera, A; García-Rodríguez, N; Stuckey, R; Wellinger, RE | 1 |
| Blay, J; Cutler, MJ; Hajducek, DM; Lowthers, EL; Richard, CL; Spagnuolo, PA | 1 |
1 review(s) available for camptothecin and Carcinogenesis
| Article | Year |
|---|---|
Targeting HER2 expression in cancer: New drugs and new indications.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinogenesis; Humans; Immunoconjugates; Mutation; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
5 other study(ies) available for camptothecin and Carcinogenesis
| Article | Year |
|---|---|
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Damage; Drug Evaluation, Preclinical; Epithelial-Mesenchymal Transition; Humans; Irinotecan; Lung Neoplasms; MAP Kinase Signaling System; Mice, Transgenic; Neoplasm Staging; Phosphorylation; Proto-Oncogene Proteins p21(ras); Resorcinols; Tumor Burden; Tumor Suppressor Protein p53 | 2017 |
LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Line, Tumor; Cellular Senescence; Chromatin; Demethylation; E2F1 Transcription Factor; G1 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Histone Demethylases; Histones; Humans; Mice; Neoplasms; Pargyline; Promoter Regions, Genetic; S Phase; Transcription Factors; Xenograft Model Antitumor Assays | 2018 |
Potential therapeutic targets for growth arrest of colorectal cancer cells exposed to PTHrP.
Topics: Animals; Apoptosis; Caco-2 Cells; Camptothecin; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; HCT116 Cells; Humans; MAP Kinase Signaling System; Mice, Nude; Models, Biological; Molecular Targeted Therapy; Parathyroid Hormone-Related Protein; Phosphorylation; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
Role for RNA:DNA hybrids in origin-independent replication priming in a eukaryotic system.
Topics: Bacterial Proteins; Camptothecin; Carcinogenesis; Cell Cycle; Cell Separation; Chromosomes; DNA; DNA Copy Number Variations; DNA Replication; DNA, Ribosomal; Electrophoresis, Gel, Two-Dimensional; Flow Cytometry; Gene Dosage; Genomic Instability; Humans; Hydroxyurea; Luminescent Proteins; Methyl Methanesulfonate; Mutation; Replication Origin; Ribonuclease H; RNA; Saccharomyces cerevisiae | 2015 |
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Lineage; Cell Movement; Chemokine CXCL12; Colonic Neoplasms; Dipeptidyl Peptidase 4; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplasm Metastasis; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2015 |